Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Antisoma, sanofi-aventis sales and marketing update

sanofi-aventis acquired exclusive, U.S. rights to Oforta fludarabine from Antisoma for $60 million in cash up front plus $5 million over five years. The

Read the full 240 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE